In tumors, dendritic cells increase production of a protein called Slc6a8 to take up creatine, which provides energy for their inflammatory activity.
See the scientific wording
Dendritic cells within tumors upregulate the creatine transporter (Slc6a8) in response to activation signals, enabling them to import creatine to support their energy demands and inflammatory function.
Indication only — weak evidence
ObservationalOne low-scoring study points this way, but the evidence is still early.
What the research says
1 study reviewedSupporting (1)
Creatine uptake promotes dendritic cell activation and enhances antitumor immunity
Cohort StudyHuman2026
The study shows increased Slc6a8 expression in tumor-infiltrating dendritic cells and in LPS-stimulated dendritic cells, establishing that activation triggers upregulation of the creatine transporter as a metabolic adaptation.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
When dendritic cells in a tumor are activated, they make more of a protein that pulls creatine inside. Inside the cell, creatine helps store and quickly release energy to keep ATP levels high. This steady energy supply keeps key signaling pathways running, which turns on genes that make the dendritic cells more active and better at stimulating killer T cells to attack the tumor.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
In tumors, dendritic cells increase production of a protein called Slc6a8 to take up creatine, which provides energy for their inflammatory activity.
Mechanism
1 studyWhen dendritic cells in a tumor get activated, they bring in more creatine to keep their energy supply stable. This steady energy keeps their inflammatory signals running, making them better at turning on T cells to fight the tumor.
When dendritic cells in a tumor are activated, they make more of a protein that pulls creatine inside. Inside the cell, creatine helps store and quickly release energy to keep ATP levels high. This steady energy supply keeps key signaling pathways running, which turns on genes that make the dendritic cells more active and better at stimulating killer T cells to attack the tumor.
Dendritic cells upregulate expression of the creatine transporter SLC6A8 in response to activation signals such as TLR ligands or inflammatory cytokines
Extracellular creatine is transported into dendritic cells via SLC6A8 and converted to phosphocreatine by creatine kinase
The phosphocreatine pool buffers intracellular ATP levels during high-energy demand, maintaining low AMP:ATP and ADP:ATP ratios
Preserved ATP levels enable sustained phosphorylation and nuclear translocation of NF-κB p65, activating inflammatory gene transcription
NF-κB-driven gene expression increases production of costimulatory molecules and proinflammatory cytokines
Activated dendritic cells enhance priming of antigen-specific CD8+ T cells, increasing their proliferation, cytokine production, and tumor infiltration
Evidence from Studies
Supporting (1)
Community contributions welcome
Creatine uptake promotes dendritic cell activation and enhances antitumor immunity
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Slc6a8 Expression in Tumor-Infiltrating Dendritic Cells Across Human Cancer Types
Systematic review and meta-analysis of peer-reviewed studies reporting Slc6a8 expression levels in tumor-infiltrating dendritic cells across human cancers, with standardized methods for activation status, creatine uptake, and inflammatory markers.
Randomized Controlled Trial of Slc6a8 Inhibition in Human Dendritic Cells During Tumor Antigen Presentation
Randomized controlled trial using human dendritic cells derived from peripheral blood mononuclear cells, randomized to Slc6a8 inhibitor or control, with measurement of intracellular creatine, ATP levels, cytokine secretion, and antigen presentation capacity after activation.
Longitudinal Cohort Study of Slc6a8 Expression and Dendritic Cell Function in Patients with Solid Tumors
Prospective cohort study tracking Slc6a8 expression, creatine levels, metabolic markers, and inflammatory cytokine profiles in dendritic cells isolated from tumor biopsies of cancer patients over a 12-month period.
In Vitro Study of Creatine Transport and Metabolic Function in Activated Human Dendritic Cells with Slc6a8 Knockdown
In vitro experiment using human dendritic cells exposed to activation signals (e.g., LPS, IFN-γ), with Slc6a8 knocked down via siRNA, measuring creatine uptake, ATP levels, mitochondrial respiration, and IL-12/TNF-α secretion compared to controls.
Mouse Model Study of Slc6a8 Deletion in Dendritic Cells on Tumor Growth and Intratumoral Inflammation
Mouse model with dendritic cell-specific Slc6a8 knockout, implanted with syngeneic tumors, measuring tumor volume, dendritic cell creatine content, metabolic flux, cytokine production, and T-cell activation over 3–6 weeks.